EMPAVELI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMPAVELI (EMPAVELI).
Pegcetacoplan is a complement C3 inhibitor that binds to complement component C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
| Metabolism | Pegcetacoplan is a pegylated peptide; metabolism involves catabolism into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Primarily excreted unchanged in urine (approximately 60-70% of administered dose) and feces (approximately 20-30% as parent drug and metabolites). Less than 1% is recovered as metabolites. |
| Half-life | Terminal elimination half-life is approximately 7-10 days. This supports once-weekly subcutaneous dosing, achieving steady-state concentrations after 3-4 weeks of weekly administration. |
| Protein binding | Approximately 95-99% bound to plasma proteins, primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 3.5-5.0 L, indicating limited extravascular distribution and confinement primarily to the vascular space, consistent with a large monoclonal antibody. |
| Bioavailability | Subcutaneous: Approximately 80-90% bioavailability following subcutaneous injection into the abdomen, thigh, or arm. |
| Onset of Action | Subcutaneous: Clinical improvement in hemolysis (elevated hemoglobin, reduced LDH) is observed within 1-2 weeks of starting therapy, with peak effects on complement activity and hemolytic markers seen after 4-6 weeks. |
| Duration of Action | Duration of therapeutic effect is sustained with weekly dosing. After discontinuation, complement activity returns to baseline within 2-4 weeks, and hemolysis may recur within 1-2 months. |
1080 mg subcutaneously once weekly for 2 weeks, then 1080 mg subcutaneously every 2 weeks thereafter.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or ESRD; use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment; use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients below 18 years. |
| Geriatric use | No specific dose adjustment recommended. Clinical studies included patients aged 65 and older; no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMPAVELI (EMPAVELI).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Pegcetacoplan is a large protein (MW ~45 kDa); likely minimal transfer into milk. M/P ratio not determined. Caution advised due to theoretical risk of immunosuppression in the infant. Use only if potential benefit to mother outweighs potential risks. |
| Teratogenic Risk | Empaveli (pegcetacoplan) is a complement inhibitor. No adequate human data exist. In animal studies, no teratogenic effects were observed at exposures up to 4 times the human clinical exposure. However, because complement system inhibition may theoretically increase risk of infections (e.g., encapsulated bacteria) that could harm the fetus, use only if clearly needed. First trimester: risk cannot be excluded; avoid unless benefit outweighs risk. Second/third trimesters: limited data; theoretical risk of maternal infection leading to fetal harm. Monitor for infections. |
■ FDA Black Box Warning
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA. EMPAVELI increases the risk of serious infections, especially those caused by encapsulated bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. Vaccinate patients according to ACIP guidelines at least 2 weeks prior to therapy; if urgent therapy is needed, provide appropriate antibiotic prophylaxis.
| Serious Effects |
["Hypersensitivity to pegcetacoplan or any excipient","Patients not vaccinated against encapsulated bacteria (unless urgent therapy is needed with appropriate antibiotic prophylaxis)"]
| Precautions | ["Serious infections caused by encapsulated bacteria","Monitor for signs of hemolysis, especially after discontinuation","Risk of thrombotic events (though less than with other complement inhibitors)","Administration reactions (including anaphylaxis)"] |
Loading safety data…
| Fetal Monitoring | Monitor for infections, especially caused by encapsulated bacteria (e.g., Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae). Ensure up-to-date vaccinations before initiating therapy. Monitor for signs of hemolysis or thrombotic microangiopathy (TMA) in patients with paroxysmal nocturnal hemoglobinuria (PNH) if therapy is interrupted. Perform regular blood counts and lactate dehydrogenase (LDH) levels. In pregnancy, monitor for pregnancy-induced hypertension and gestational diabetes. |
| Fertility Effects | No human data on fertility. In animal studies, no adverse effects on male or female fertility were observed at doses up to 4 times the human clinical exposure. Theoretical risk due to complement inhibition on reproductive tissues is unknown. |